Latest Anti-diabetic drug Stories
Akesis Pharmaceuticals, Inc.
Some people with type 2 diabetes can control the disease and avoid insulin injections by using multiple classes of oral medications, U.S. researchers say. Principal investigator Dr.
PARSIPPANY, NJ, April 15 /PRNewswire/ -- Daiichi Sankyo announced today that Welchol(TM) (colesevelam HCl) has been added to the American College of Endocrinology (ACE) and American Association of Clinical Endocrinologists (AACE) 2008 "Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus." The Road Maps are updated regularly by ACE/AACE to provide physicians with the latest and most comprehensive treatment options for their patients with type 2 diabetes mellitus.
By Kathleen Fackelmann Donald McEwen was driving on I-480 when he saw an ad on the back of a bus recruiting people for a study on diabetes. He picked up his cellphone almost immediately. "I was scared to death," he says now about the pain, fatigue and vision problems caused by his diabetes.
Federal researchers who tried to reduce heart attacks among diabetics by driving their blood sugar to low levels found that more patients were dying instead.
RESTON, Va., Jan. 31 /PRNewswire/ -- Millions of people suffer from the chronic pain and complications of autonomic neuropathy, a degenerative nerve disease. A new book suggests that this suffering can be effectively treated by raising blood sugar levels at key points.
By Kim, M J; Rolland, Y; Cepeda, O; Gammack, J K; Morley, J E Abstract Most persons with diabetes mellitus are over the age of 60 years. Males develop diabetes more commonly than females. Older diabetics tend to have both impaired insulin release as well as insulin resistance.
By Will Boggs, MD NEW YORK (Reuters Health) - Better metabolic control of type 2 diabetes can lead to improved "working memory" -- the type of memory people use to keep information in their minds for short-periods of time and to complete day-to-day activities.
By Susan Heavey WASHINGTON (Reuters) - An experimental diabetes drug that may increase the risk of congestive heart failure and death should not be allowed on the market despite initial support from U.S. regulators, a consumer group said on Monday.
An experimental diabetes drug that may increase the risk of congestive heart failure and death should not be allowed on the market despite initial support from U.S. regulators, a consumer group said on Monday.
- A serpent whose bite was fabled to produce intense thirst.